Grant: Alliance Grants
Simon Fraser University
$63,000.00
Automated synthesis of bioactive metal complexes
EF 2024-25
Résumé
This proposal is a collaboration between the Walsby Group at SFU (academic partner) and Bold Therapeutics (industrial partner). The goal of the work proposed is to develop an automated synthetic method to produce large collections of chemically-related metal complexes. This approach uses a synthesis robot at SFU that performs synthesis on a scale that would be prohibitively time-consuming if performed manually. The benefits of large libraries of complexes are the ability to relate chemical structures of metal complexes to reactivity, and improved chances for discovery of compounds with novel activity. The specific compounds chosen for this project have potential applications as pharmaceuticals, imaging agents, and catalysts. Initially, work will focus on ruthenium compounds with "pyridine benzimidazole" ligands, which have been shown by the Walsby group, in collaboration with Bold Therapeutics, to have potential as anticancer agents. To date only a small number of these compounds have been synthesized and automated synthesis will be used to dramatically expand this to almost 200 derivatives in the first round of development. This will enable systematic variation of molecular properties such as lipophilicity, overall charge, solubility, stability, and geometry. Analysis of the activity of the metal-complex libraries will be conduced at the Centre for High-Throughput Chemical Biology (cHTCB) at SFU. This world-leading facility uses automated methods for the studies of large libraries of compounds and is ideally suited to characterize the biological activities of the compounds generated by this proposal. Properties characterized will include general cytotoxicity and details of reactivity within different components within cells, such as mitochondria and nuclei. These large-scale studies will enable our research team to relate the fundamental chemical properties of the metal complexes to biological activation, to give structure-activity relationships (SAR). Combining the expertise of the Walsby Group and Bold Therapeutics will benefit Canada through the development of an invaluable method for the systematic synthesis of novel reactive metal complexes for a range of applications.
Programme
Alliance Grants
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
597449-2024
Name nom
Walsby, Charles CJ
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
63000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
3600
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Inorganic chemistry
Research subject fr
Chimie inorganique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Automated synthesis of bioactive metal complexes
Keywords
automated synthesis; high-throughput screening; ligand design; metal complexes; organometallic chemistry; structure-activity relationships
Application summary
This proposal is a collaboration between the Walsby Group at SFU (academic partner) and Bold Therapeutics (industrial partner). The goal of the work proposed is to develop an automated synthetic method to produce large collections of chemically-related metal complexes. This approach uses a synthesis robot at SFU that performs synthesis on a scale that would be prohibitively time-consuming if performed manually. The benefits of large libraries of complexes are the ability to relate chemical structures of metal complexes to reactivity, and improved chances for discovery of compounds with novel activity. The specific compounds chosen for this project have potential applications as pharmaceuticals, imaging agents, and catalysts. Initially, work will focus on ruthenium compounds with "pyridine benzimidazole" ligands, which have been shown by the Walsby group, in collaboration with Bold Therapeutics, to have potential as anticancer agents. To date only a small number of these compounds have been synthesized and automated synthesis will be used to dramatically expand this to almost 200 derivatives in the first round of development. This will enable systematic variation of molecular properties such as lipophilicity, overall charge, solubility, stability, and geometry. Analysis of the activity of the metal-complex libraries will be conduced at the Centre for High-Throughput Chemical Biology (cHTCB) at SFU. This world-leading facility uses automated methods for the studies of large libraries of compounds and is ideally suited to characterize the biological activities of the compounds generated by this proposal. Properties characterized will include general cytotoxicity and details of reactivity within different components within cells, such as mitochondria and nuclei. These large-scale studies will enable our research team to relate the fundamental chemical properties of the metal complexes to biological activation, to give structure-activity relationships (SAR). Combining the expertise of the Walsby Group and Bold Therapeutics will benefit Canada through the development of an invaluable method for the systematic synthesis of novel reactive metal complexes for a range of applications.